BOSTON SCIENTIFIC CORP — Director's Dealing 2020

Feb 18, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2020-02-14

Reporting Person: Mackey Edward F (EVP, Operations)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-14	Common Stock	A	20161.0000	$0.0000	Acquired	55548.0000	Direct
2020-02-14	Common Stock	F	7520.0000	$42.3100	Disposed	48028.0000	Direct
2020-02-15	Common Stock	M	2768.0000	$0.0000	Acquired	50796.0000	Direct
2020-02-15	Common Stock	F	1257.0000	$42.3100	Disposed	49539.0000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-15	Deferred Stock Units	$	M	2768.0000	Disposed	2023-02-15	Common Stock (2768.0000)	Direct

Footnotes

F1: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

F2: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F3: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.